Exhibit 107
Calculation of Filing Fee Table
Form S-8
(Form Type)
Nektar Therapeutics
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered Securities
Security Type | Security Class Title | Fee Calculation Rule | Amount Registered (1) | Proposed Maximum Offering Price Per Unit | Maximum Aggregate Offering Price | Fee Rate | Amount of Registration Fee | |||||||||||||
Equity | Common Stock, $0.0001 par value per share | Other (2) | 5,000,000 (3) | $ | 3.86 (2) | $ | 19,275,000 | $ | 0.0000927 | $ | 1,786.79 | |||||||||
Total Offering Amounts | $ | 19,275,000 | — | |||||||||||||||||
Total Fees Previously Paid | — | |||||||||||||||||||
Total Fee Offsets | — | |||||||||||||||||||
Net Fee Due | $ | 1,786.79 |
(1) | Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of common stock, par value $0.0001 per share (the “Common Stock”), which become issuable under the above-named plan by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without the receipt of consideration which results in an increase in the number of the Registrant’s outstanding shares of common stock. |
(2) | Estimated in accordance with Rules 457(c) and (h) under the Securities Act solely for the purpose of calculating the registration fee. The price represents the average of the high and low prices of the Common Stock as reported on the Nasdaq Global Select Market on August 1, 2022. |
(3) | Consists of 5,000,000 shares issuable under the Nektar Therapeutics Amended and Restated 2017 Performance Incentive Plan, pursuant to such plan. |